FDA Licenses New Hemophilia Treatment

FDA recently licensed a new treatment for hemophilia A called Xyntha. Xyntha, which is made by Wyeth Pharmaceuticals, is a genetically engineered version of factor VIII, a protein essential for blood clotting that is decreased or absent in patients with hemophilia A.

Xyntha is produced without additives from human or animal material. This provides hemophilia A patients with an additional treatment option that can further minimize the risk of infection from the product.

FDA Patient Safety News: May 2008

Your rating: None